Daiichi Sankyo discontinues development of nafamostat inhalation formulation for COVID-19 in Japan June 16, 2021
Harbour BioMed and Dana-Farber Cancer Institute to codevelop novel biotherapies for cancer June 16, 2021
Ashvattha reports phase II interim data on OP-101 to treat hyperinflammation in severe COVID-19 June 16, 2021
ORIN-1001 shows promising preliminary antitumor activity in heavily pretreated solid tumors June 16, 2021
RSS